inecalcitol + imatinib

**Inecalcitol + imatinib** is a combination treatment investigated for potential *synergistic antineoplastic activity* in cancers, particularly chronic myeloid leukemia (CML). Inecalcitol is a vitamin D₃ analog with anti-proliferative, pro-apoptotic, and anti-angiogenic effects, while imatinib is a small-molecule BCR-ABL tyrosine kinase inhibitor that disrupts key oncogenic pathways in CML. Studies in cell lines demonstrate that this combination can lead to enhanced cell killing compared to each agent alone in certain CML cell models, suggesting a synergistic mode of action. This regimen is under investigation and not an approved standard of care[1][3][5].